(AOF) – Good news for Abivax. The company announced on Wednesday evening excellent efficacy and safety results after one year of treatment in the phase 2b maintenance study of ABX464 in ulcerative colitis. “Final preparations for the international Phase 3 clinical program with ABX464 in UC are underway, with enrollment of the first patients planned for the third quarter of 2022,” added Abivax.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.